ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Cytomeglovirus"

  • 2017 American Transplant Congress

    IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-CMV IgG, Resulting in Inhibition of Antibody (Ab)-Mediated NK Cell Activation in Kidney Transplant Patients (KTX Pts).

    B.-H. Shin,1 S. Ge,1 M. Chu,1 J. Choi,1 L. Winstedt,2 C. Kjellman,2 S. Louie,1 A. Vo,1 A. Peng,1 S. Jordan,1 M. Toyoda.1

    1Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Hansa Medical, Lund, Sweden

    Background: Viral infections represent significant morbidity factors for KTx Pts. Ab-dependent cell-mediated cytotoxicity (ADCC) is a major pathway to eliminate virally infected cells and is…
  • 2017 American Transplant Congress

    Incidence of Cytomegalovirus Infection Among Liver Transplant Recipients Maintained on a Cyclosporine vs. Tacrolimus-Based Immunosuppression Regimen.

    C. Burrelli, M. Bradley, S. Pouch, E. Elkhammas, H. Winters.

    The Ohio State University Wexner Medical Center, Columbus, OH

    Background: Cytomegalovirus (CMV) is the most common viral pathogen that affects patient outcomes after liver transplant. Potent immunosuppressive agents predispose patients to an increased risk…
  • 2017 American Transplant Congress

    Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.

    P. Klem,1 L. Al-Omar,2 J. Cooper,2 S. Davis,2 J. Gralla,2 D. Choe,1 A. Wiseman.2

    1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora

    Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…
  • 2017 American Transplant Congress

    Improving Donor Screening for Cytomegalovirus (CMV): Is CMV IgG Avidity Better Than CMV IgM?

    H. Prince,1 M. Nowicki.1,2

    1Donor Screening Laboratory, VRL Eurofins, Los Angeles, CA; 2Mendez National Institute of Transplantation Foundation, Los Angeles, CA

    Study purpose: It is standard practice to test organ donors for CMV IgM as a marker of recent CMV infection (defined as primary infection within…
  • 2017 American Transplant Congress

    Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) infection is a major cause of morbidity, mortality, and shortened graft survival in kidney transplant recipients. Efforts to prevent CMV infection have traditionally…
  • 2017 American Transplant Congress

    Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV).

    P. Baum,1 J. Yao,2 A. Butcher,1 P. Hemyari,1 A. Valsamakis,3 S. Young.4

    1Roche Diagnostics, Pleasanton, CA; 2Mayo, Rochester, MN; 3JHMI, Baltimore, MD; 4Tricore, Albuquerque, NM

    cobas CMV is a new, automated, high-throughput assay for use on the cobas 6800/8800 systems that quantifies CMV DNA in EDTA-plasma. It can be run…
  • 2017 American Transplant Congress

    Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…
  • 2017 American Transplant Congress

    Cytomegalovirus Renal Infection: Rare Manifestation of a Common Post-Transplant Viral Infection — A Case Series.

    M. Posadas Salas, J. Thompson, T. Ngo, S. Self.

    MUSC, Charleston, SC

    Cytomegalovirus is the most common viral infection in organ transplant recipients. CMV disease commonly manifests as meningoencephalitis, pneumonitis, hepatitis, and colitis. Kidney involvement of CMV…
  • 2017 American Transplant Congress

    Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).

    C. Danthu,1 M. Gomes-Mayeras,1 D. Andouard,2 E. Munteanu,1 R. Moulinas,1,4 G. Ligat,2 S. Hantz,1,2 J. Rerolle,3 F. Garnier,1 M. Essig,3 S. Alain.1,2,4

    1National Reference Center for CMV-Virology, CHU Limoges, Limoges, France; 2UMR Inserm 1092, Université Limoges, Limoges, France; 3Nephrology, CHU Limoges, Limoges, France; 4GenoLim/Biscem Genomic Platform, Université Limoges, Limoges, France

    Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…
  • 2017 American Transplant Congress

    Cost Effectiveness of Post-Prophylaxis Screening Strategies for Cytomegalovirus Viremia in CMV D+R- Kidney Transplant Recipients.

    C. Puttarajappa,1 S. Hariharan,1 K. Smith.2

    1Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA; 2Section of Decision Sciences, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

    Purpose: To assess cost-effectiveness(CE) of screening for CMV after 6 months of valganciclovir prophylaxis in CMV high-risk (D+R-) kidney transplant recipients.Methods: A Markov model was…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 33
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences